Market News / Story
Pfizer Inc. (PFE) Wins FDA OK for TUKYSA Front-Line Maintenance in HER2+ MBC
·
Pfizer received FDA approval for TUKYSA (tucatinib) with trastuzumab and pertuzumab as maintenance treatment for adults with unresectable locally advanced or metastatic HER2+ breast cancer following induction treatment. Material Details #DetailAI Analyst View1FDA approves TUKYSA front-line useLabel expansion can drive higher eligible patient numbers and revenue potential.2Chemo-free maintenance regimenDifferentiated profile may aid adoption and payer/formulary…